Anteris Says Heart Valve Clinical Data Shows No Valve-Related Mortality
MT Newswires Live
Nov 17, 2025
Anteris Technologies (ASX:AVR) said clinical outcomes for its transcatheter heart valve DurAVR in 100 severe aortic stenosis patients with small aortic annuli showed no moderate or severe paravalvular leaks and no valve-related mortality, according to a Monday filing with the Australian bourse.
The results also showed 97% freedom from moderate or severe prosthesis-patient mismatch (PPM) in a group of small annuli patients, the filing said.
Moderate to severe PPM is independently associated with reduced survival and increased risk of structural valve deterioration, the filing added.
Shares of the company fell 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.